Altimmune to Present at Dawson James Securities 4th Annual Small Cap Growth Conference

GAITHERSBURG, Md., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. ALT, a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer will provide a corporate overview at the Dawson James Securities 4^th Annual Small Cap Growth Conference being held at the Wyndham Grand Jupiter Hotel, Jupiter, Florida.  Details of the presentation are as follows:

Dawson James Securities 4^th Annual Small Cap Growth Conference Details:

Date:                     Tuesday, October 30, 2018

Time:                     4:00 pm

Location:                Wyndham Grand Jupiter Hotel, Jupiter, Florida

About Altimmune

Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of infectious disease. NasoVAX our influenza vaccine candidate has unique characteristics, stimulating multiple arms of the immune system that offer the potential to stop infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is a next-generation anthrax vaccine candidate that is intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.

Forward-Looking Statement 

Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. (the "Company") may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: the terms of the Company's Series B preferred stock offering and related warrants; our lack of financial resources and access to capital; realizing the benefits of the merger between Altimmune, Inc. and PharmAthene, Inc.; our ability to utilize the benefits of our tax assets and the results of a tax examination initiated by the IRS; clinical trials and the commercialization of proposed product candidates (such as marketing, regulatory, product liability, supply, competition, dependence on third parties and other risks); the regulatory approval process; dependence on intellectual property; the Company's BARDA contract and other government programs, reimbursement and regulation. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, which are available at www.sec.gov.

Contacts

Bill Enright                

President and CEO       

Phone: 240-654-1450         

Email: enright@altimmune.com   

Ashley R. Robinson

Managing Director LifeSci Advisors

Phone: 617-535-7742

Email: arr@lifesciadvisors.com